Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | STAT1 | P42224 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24029313 | 0.88 | OPRM1 (0.47) | OPRM1KCNH2HRH3NPC1RAB9A | |
| SCHEMBL24112355 | 0.86 | NPC1 (0.48) | OPRM1CCR5KCNH2HRH3NPC1 | |
| SCHEMBL24450336 | 0.85 | NPC1 (0.47) | OPRM1CCR5KCNH2HRH3NPC1 | |
| SCHEMBL24112381 | 0.76 | NPC1 (0.50) | OPRM1KCNH2HRH3NPC1RAB9A | |
| SCHEMBL25760660 | 0.75 | NPC1 (0.41) | CCR5KCNH2HRH3NPC1RAB9A | |
| SCHEMBL24450335 | 0.74 | RAB9A (0.49) | OPRM1KCNH2HRH3NPC1RAB9A | |
| SCHEMBL28714355 | 0.74 | SLC18A3 (0.49) | OPRM1CCR5KCNH2HRH3NPC1 | |
| SCHEMBL12386859 | 0.73 | DRD2 (0.55) | OPRM1CCR5KCNH2HRH3ALDH1A1 | |
| SCHEMBL24019673 | 0.73 | HTT (0.54) | NPC1RAB9ASMN1; SMN2MAPTSTAT1 | |
| SCHEMBL12609029 | 0.72 | HRH3 (0.56) | OPRM1CCR5KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2021-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11312704-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTSV, CTRL, CTSL | OPRM1 4652/4885CCR5 639/4885KCNH2 4312/4885 |
| US-20210355111-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSV, CTSL | OPRM1 4719/4885CCR5 666/4885KCNH2 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.